Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Indicated for the adjuvant treatment of melanoma patients with lymph node involvement who have undergone complete resection.